• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VANTEDGE MEDICAL ANNOUNCES NEW CHIEF EXECUTIVE OFFICER

    1/11/24 10:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous
    Get the next $NOVT alert in real time by email

    Accomplished Med-Tech Executive Brian King Adds to Existing Role with Company

    SAN JOSE, Calif., Jan. 11, 2024 /PRNewswire/ -- Vantedge Medical ("Vantedge" or "Vantedge Medical"), a portfolio company of Aterian Investment Partners ("Aterian"), is pleased to announce that Brian King is now serving as CEO and Chairman of Vantedge Medical. Brian has served as Executive Chairman of the Company since February 2022.

    Brian King, CEO and Chairman, Vantedge Medical

    Brian brings a more than 25-year track record of success in the healthcare industry including both OEM and outsourced manufacturing, with both public and privately held companies. Previously, Brian served as CEO of Viant Medical where he led a complete transformation of a focused, niche $220 Million organization into a leading $1 Billion global services provider to the medical industry with twenty-four locations and more than six thousand employees. In addition to his experience with Viant Medical, Brian spent more than a decade with Covidien in roles of increasing responsibility, culminating with his position as Group President of Covidien's Emerging Markets. Under Brian's leadership, this division was responsible for nearly 60% of Covidien's growth, generating more than $2 Billion of Revenue, and employing more than 4,500 employees.

    Brian has also contributed his experience to multiple healthcare industry related Boards of Directors including Novanta (NASDAQ:NOVT), Atalys, Acrotec Group (Switzerland), PCI Pharma Services (top performing portfolio company of THL's fund VII), and Viant Medical. He has also served on the boards of Houston Street and B&C Research Corp.

    Brian graduated from the United States Naval Academy with honors where he was a Regimental Commander and was awarded the 'Cup of 1897' senior class leadership award. He earned a master's from Penn State University in Civil Engineering, as well as an MBA from Harvard University. Brian is active with several philanthropic organizations including the Fisher House foundation (Veteran assistance), Caring for Cambodia, and the Salvation Army. Finally, Brian served his country as a carrier-based combat jet pilot and was qualified to pilot three different types of jet aircraft.

    "As I look to the future of Vantedge, I am both excited and humbled to have this opportunity to take on the additional role as CEO and to work alongside our dedicated employees. Together, we will execute our vision – to be the premier metals-based MedTech solutions partner from concept to full-scale manufacturing. We have an amazing team of professionals coupled with the most comprehensive suite of unique and necessary process capabilities in the medical technology space. Our mission is strong and intentionally aligns with those of our valued medical OEM customers because, as partners, we can truly make a difference in the lives of patients and their families," states Brian King, CEO and Chairman of Vantedge.

    Brandon Bethea, Co-Founder and Partner at Aterian, said "I am elated to be able to announce Brian's appointment as Chief Executive Officer and Chairman of Vantedge Medical. Brian possesses a demonstrated track record of success with some of the most admired companies in the healthcare industry as well as a powerful and unique set of leadership experiences. Vantedge could not be more fortunate to have Brian add CEO to his existing responsibilities as Chairman. Having worked closely with Brian in the last two years, I am certain that Brian's relentless focus on world class product quality, organizational excellence and servant leadership will benefit not just Vantedge, but our customers and supply chain partners as well." 

    This news follows a November 8th announcement from the company as it recently underwent a strategic transformation to combine the collective expertise of Vander-Bend Manufacturing, Inc., TMK Manufacturing, JL Haley, Swiss Precision Machining, and Omni Components under a single, cohesive brand - Vantedge Medical.

    About Vantedge Medical

    Vantedge Medical is the premier metals-based med-tech solutions partner from concept to full-scale manufacturing. At the forefront of precision engineering and innovation, the Vantedge team specializes in the development and manufacturing of vital components and capital equipment for medical markets such as Robotic Assisted Surgery, Orthopedics, Surgical Instruments, Dental, and more. The organization's teams work in unison, collaborating and problem-solving at eight sites across the United States, certified to ISO 9001 and 13485 with FDA registration to serve the manufacturing needs of the top Medical Original Equipment Manufacturers (OEMs) around the globe.

    For more information, please visit http://www.vantedgemedical.com

    About Aterian Investment Partners

    Aterian Investment Partners is a private equity firm that invests in industry-leading, middle market businesses. In collaboration with management, Aterian holistically supports organizations with a focus on strategic positioning, people, processes, equipment, technology, and product innovation among others. With offices in New York and Florida, Aterian has raised cumulative equity commitments of more than $2 billion since its founding in 2009.

    For more information, please visit http://www.aterianpartners.com

    Vantedge Medical is the premier metals-based med-tech solutions partner from concept to full-scale manufacturing. (PRNewsfoto/Vantedge Medical)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vantedge-medical-announces-new-chief-executive-officer-302031995.html

    SOURCE Vantedge Medical

    Get the next $NOVT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NOVT

    DatePrice TargetRatingAnalyst
    5/11/2022Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $NOVT
    SEC Filings

    View All

    SEC Form 10-K filed by Novanta Inc.

    10-K - NOVANTA INC (0001076930) (Filer)

    2/23/26 4:57:30 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NOVANTA INC (0001076930) (Filer)

    2/23/26 4:45:25 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 144 filed by Novanta Inc.

    144 - NOVANTA INC (0001076930) (Subject)

    1/9/26 12:10:45 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Leadership Updates

    Live Leadership Updates

    View All

    IDEX Corporation Appoints Stephanie Disher and Matthijs Glastra to Board of Directors; David Parry and Livingston Satterthwaite to Retire

    IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl

    2/20/25 5:07:00 PM ET
    $ATMU
    $IEX
    $NOVT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Fluid Controls
    Industrials

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    $NOVT
    Financials

    Live finance-specific insights

    View All

    Novanta Announces Financial Results for the Fourth Quarter and Full Year 2025

    Fourth Quarter 2025 GAAP Revenue increased 9% to $258 million, and GAAP Diluted EPS was $0.45 Fourth Quarter 2025 Adjusted Diluted EPS was $0.91, increased 20%, and Adjusted EBITDA was $61 million, increased 17% Full Year 2025 GAAP Revenue increased 3% to $981 million, and GAAP Diluted EPS was $1.47 Full Year 2025 Adjusted Diluted EPS was $3.29, and Adjusted EBITDA was $221 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2025. Financial Highlights Three Months Ended December 31,    

    2/23/26 4:45:00 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026

    Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter 2025 results on Tuesday, February 24, 2026. The Company will host a conference call on Tuesday, February 24, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the

    1/22/26 11:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Announces Financial Results for the Third Quarter 2025

    Third Quarter 2025 GAAP Revenue increased 1.4% to $247.8 million Third Quarter 2025 GAAP Net Income of $10.7 million Third Quarter 2025 GAAP Diluted Earnings Per Share of $0.30 Third Quarter 2025 Adjusted EBITDA of $58.1 million Third Quarter 2025 Adjusted EPS of $0.87 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) September 26,   September 27,   2025   2024 GAAP  

    11/3/25 5:00:00 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novanta Inc.

    SC 13G/A - NOVANTA INC (0001076930) (Subject)

    11/14/24 1:22:36 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G filed by Novanta Inc.

    SC 13G - NOVANTA INC (0001076930) (Subject)

    2/14/24 10:02:59 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G/A filed by Novanta Inc. (Amendment)

    SC 13G/A - NOVANTA INC (0001076930) (Subject)

    2/13/24 5:09:44 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Glastra Matthijs sold $899,239 worth of shares (6,500 units at $138.34), decreasing direct ownership by 9% to 63,261 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    3/4/26 4:24:06 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Co-Chief Operating Officer Ravetto Charles Guy Jr converted options into 825 shares and covered exercise/tax liability with 243 shares, increasing direct ownership by 4% to 16,116 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    2/26/26 4:14:18 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Chief Financial Officer Buckley Robert converted options into 5,426 shares and covered exercise/tax liability with 2,624 shares, increasing direct ownership by 3% to 96,616 units (SEC Form 4)

    4 - NOVANTA INC (0001076930) (Issuer)

    2/26/26 4:11:55 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novanta Announces Financial Results for the Fourth Quarter and Full Year 2025

    Fourth Quarter 2025 GAAP Revenue increased 9% to $258 million, and GAAP Diluted EPS was $0.45 Fourth Quarter 2025 Adjusted Diluted EPS was $0.91, increased 20%, and Adjusted EBITDA was $61 million, increased 17% Full Year 2025 GAAP Revenue increased 3% to $981 million, and GAAP Diluted EPS was $1.47 Full Year 2025 Adjusted Diluted EPS was $3.29, and Adjusted EBITDA was $221 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2025. Financial Highlights Three Months Ended December 31,    

    2/23/26 4:45:00 PM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026

    Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter 2025 results on Tuesday, February 24, 2026. The Company will host a conference call on Tuesday, February 24, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the

    1/22/26 11:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    Novanta to Present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026

    Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Chuck Ravetto, Chief Operating Officer, will be participating at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026, which is being held virtually. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation wit

    12/18/25 11:00:00 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous

    $NOVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novanta upgraded by William Blair

    William Blair upgraded Novanta from Mkt Perform to Outperform

    5/11/22 6:19:56 AM ET
    $NOVT
    Industrial Machinery/Components
    Miscellaneous